PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
-0.01
%
−1,07%
Latest
0.928
High
0.928
Low
0.928
Volume
2 923
Turnover (SEK)
2 713
Market Value (MSEK)
46,9
Time (Latest trade)
2025-03-13 14:11

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Björn Sivik (tf)

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 51,56 51,56 2025-03-11
Vict Th Engwalls Stiftelse 2,75 2,75 2024-12-23
Arne Skogvall 2,20 2,20 2024-12-23
Arne Arvidsson 1,72 1,72 2024-12-23
Avanza Pension 1,41 1,41 2024-12-23
Nordnet Pensionsförsäkring 0,77 0,77 2024-12-23
Staffan Engelbert Bodén 0,59 0,59 2024-12-23
Tommy Johansson 0,59 0,59 2024-12-23
Merrick Lee Tabor 0,45 0,45 2024-12-23
Monica Billgert 0,44 0,44 2024-12-23
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2025-05-01 Delårsrapport 2025-Q1

  • 2025-08-21 Delårsrapport 2025-Q2

  • 2025-11-20 Delårsrapport 2025-Q3

  • 2026-02-19 Bokslutskommuniké 2025